Search Results for: DNA VACCINE TECHNOLOGY A Vaccine
Articles
Nuvec: A Breakthrough Technology for mRNA/pDNA Delivery for Vaccines & Cancer Treatments February 27, 2019
N4 Pharma Plc, a specialist pharmaceutical company, is developing Nuvec – a unique non-viral adjuvant delivery system for vaccines and...DNA VACCINE TECHNOLOGY – A Vaccine Breakthrough That Could Change Lives & Enable Vaccine Development Programs August 31, 2015
William Hearl, PhD, asks what if there was the potential for a better and safer treatment for allergies, a less-toxic cancer therapy, or a breakthrough treatment to improve the health of a pet or valuable livestock? What if you could employ a new, patented technology that may make these treatments possible?
Evaxion Biotech Expands Its EVX-03 DNA Vaccine Program Into Non-Small Cell Lung Cancer June 23, 2022
Evaxion Biotech A/S recently announced it has selected EVX-03 as the product candidate within its DNA technology platform to target...Matinas BioPharma & BioNTech Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines April 11, 2022
Matinas BioPharma and BioNTech SE recently announced they have entered into an exclusive research collaboration to evaluate the combination of mRNA formats and….
Allergy Therapeutics Selects AGC Biologics to Manufacture Novel Peanut Allergy Vaccine Candidate March 31, 2022
AGC Biologics recently announced a new partnership with Allergy Therapeutics, the fully integrated specialty pharmaceutical company specializing in allergy vaccines. The...Celsion Corporation Advances Proof of Concept to Non-human Primate Challenge Study Against SARS-CoV-2 With In-Process Vaccine Candidate January 31, 2022
Celsion Corporation recently announced it has engaged BIOQUAL, Inc., a preclinical testing contract research organization, to conduct a non-human primate (NHP) challenge study with Celsion’s DNA-based approach for….
Provectus Biopharmaceuticals Provides Update on Research into PV-10 Immunotherapy as an Immune Adjuvant for Making Vaccines Work Better January 27, 2022
Provectus recently provided an update on research of its investigational immunotherapy PV-10 (rose bengal sodium, a halogenated xanthene small molecule)...Univercells Acquires SynHelix, Entering Into Synthetic Biology & the Race to Next-Generation DNA Synthesis January 6, 2022
Univercells S.A. (Univercells) recently announced its acquisition of SynHelix, a biotechnology company that aims to debottleneck biotherapeutics development through an unprecedented robust, scalable, and….
Celsion Reports T-cell & B-cell Response From In Vivo Studies With its PLACCINE DNA Vaccine Platform September 8, 2021
Celsion Corporation recently announced results from preclinical in vivo studies showing production of antibodies and cytotoxic T-cell response specific to...Dyadic Announces Technology Transfer & Licensing Agreement With South Africa’s Rubic Consortium July 28, 2021
Dyadic International, Inc. recently announced it signed a COVID-19 vaccine technology transfer and licensing agreement with the Rubic Consortium, a...Catalent Acquires Additional Facility at its Gosselies, Belgium, Campus for Commercial-Scale Plasmid DNA Manufacturing May 6, 2021
Catalent and Promethera Biosciences recently announced that Catalent has acquired Promethera’s cell therapy manufacturing subsidiary, Hepatic Cell Therapy Support SA (HCTS), including its….
AstraZeneca’s & J&J’s COVID-19 Vaccines Manufacturing Face Viral Vector Shortages March 25, 2021
The latest wave of COVID-19 vaccines - those from AstraZeneca and Johnson & Johnson (J&J) - are recombinant vector vaccines,...IMMUNE ACTIVATORS – Enhancing Cell Adhesion to Safely Improve Effectiveness of Vaccines & Cancer Immunotherapies March 1, 2021
Siddhartha De, PhD, and Peter Vanderslice, PhD, present their research on the use of proprietary, orally available compounds that can activate the immune system to enhance the effectiveness of vaccines as well as immuno-oncology therapies for cancer, especially in patient populations that are most vulnerable to disease.
Akston Biosciences & LakePharma Announce Strategic Partnership to Manufacture Second-Generation COVID-19 Vaccine January 5, 2021
Akston Biosciences and LakePharma recently announced they have established a strategic partnership in which LakePharma will manufacture commercial quantities of Akston’s...Recipharm Signs Agreement With Arcturus Therapeutics to Support the Manufacture of LUNAR-COV19 (ARCT-021) Vaccine Candidate October 7, 2020
Recipharm has recently entered into an agreement with Arcturus Therapeutics, a leading US-based clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and….
PLATFORM TECHNOLOGY – Morphomer(TM) & SupraAntigen(TM) Platforms: Targeting Misfolded Proteins in Neurodegenerative Disorders October 1, 2020
Andrea Pfeifer, PhD, details the efforts to develop the therapeutic and diagnostic tools necessary to enable precision medicine approaches targeting the right protein, at the right time, in the right patient.
Arcturus Therapeutics Announces Dosing of its COVID-19 Vaccine Candidate in Phase 1/2 Study August 12, 2020
Arcturus Therapeutics Holdings Inc. recently announced that all subjects in the first cohort have been dosed in the Phase 1/2...Arcturus Therapeutics & Catalent Announce Partnership to Manufacture mRNA-Based COVID-19 Vaccine May 5, 2020
Arcturus Therapeutics Holdings Inc. and Catalent, Inc.recently announced a partnership to support the expected manufacture of Arcturus’ COVID-19 mRNA vaccine candidate (LUNAR-COV19), intended to….
OncoSec Collaborates With Providence Cancer Institute to Conduct First-in-Human Trial of Investigational Vaccine to Prevent COVID-19 April 9, 2020
OncoSec Medical Incorporated recently announced that Providence Cancer Institute, a part of Providence St. Joseph Health, is pursuing a first-in-human Phase 1 clinical trial of OncoSec’s novel….
Arcturus Therapeutics & Duke-NUS Medical School Partner to Develop a COVID-19 Vaccine March 5, 2020
Arcturus Therapeutics and Duke-NUS Medical School (Duke-NUS) recently announced their partnership to develop a Coronavirus….
